DOCK7: A Protein with Potential as A Drug Target and Biomarker

Target Name: DOCK7

NCBI ID: G85440

DOCK7

DOCK7: A Protein with Potential as A Drug Target and Biomarker

DOCK7 (DOCK7_HUMAN) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the DOCK family of proteins, which are involved in the delivery and processing of proteins to their final destinations.

One of the unique features of DOCK7 is its ability to interact with small molecules, such as drugs and toxins. This interaction makes DOCK7 an attractive drug target for researchers, as it allows for the development of new treatments for various diseases.

DOCK7 has been shown to play a role in a number of important biological processes, including cell signaling, inflammation, and the regulation of ion and water transport. It is also involved in the development and maintenance of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising aspects of DOCK7 as a drug target is its potential to treat a wide range of diseases, due to its broad and diverse functions. For example, DOCK7 has been shown to be involved in the development and progression of cancer, and may be a useful target for cancer treatments. It has also been shown to play a role in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, and may be a useful target for these conditions.

In addition to its potential as a drug target, DOCK7 has also been shown to be a valuable biomarker for a number of diseases. For example, it has been used as a biomarker for various types of cancer, and has been shown to be highly sensitive to changes in cancer status. It may also be a useful biomarker for neurodegenerative diseases, as its levels have been shown to be affected by the progression of these conditions.

DOCK7 is also a good candidate for a diagnostic marker, as its expression has been shown to be sensitive to a variety of factors, such as disease stage, treatment, and patient age. This makes it a promising tool for the diagnosis and monitoring of various diseases.

In conclusion, DOCK7 (DOCK7_HUMAN) is a protein that has the potential to be a drug target and a valuable biomarker for a wide range of diseases. Further research is needed to fully understand its functions and potential as a drug and diagnostic tool.

Protein Name: Dedicator Of Cytokinesis 7

Functions: Functions as a guanine nucleotide exchange factor (GEF), which activates Rac1 and Rac3 Rho small GTPases by exchanging bound GDP for free GTP. Does not have a GEF activity for CDC42. Required for STMN1 'Ser-15' phosphorylation during axon formation and consequently for neuronal polarization (PubMed:16982419). As part of the DISP complex, may regulate the association of septins with actin and thereby regulate the actin cytoskeleton (PubMed:29467281). Has a role in pigmentation (By similarity). Involved in the regulation of cortical neurogenesis through the control of radial glial cells (RGCs) proliferation versus differentiation; negatively regulates the basal-to-apical interkinetic nuclear migration of RGCs by antagonizing the microtubule growth-promoting function of TACC3 (By similarity)

The "DOCK7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DOCK7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets